Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 15:46:e-rbgo11.
doi: 10.61622/rbgo/2024AO11. eCollection 2024.

Sacral neuromodulation therapy for urinary and defecatory disorders: experience in a Latin American public hospital

Marcelo Mass-Lindenbaum  1   2   3 , Diego Arévalo-Vega  1   4 , Isidora Aleuanlli  5 , Fernanda Santis-Moya  1   2 , Andrea Maluenda  1   2   6 , Eitan Dines  2 , Miriam Cohen-Vaizer  7 , Álvaro Saavedra  1   2   8 , Trinidad Raby  1   2   5 , Bernardita Blumel  1   2   9 , Rodrigo Cuevas  1   2   5 , Simone Pohlhammer  1   2   10 , Gabriela Alarcon  1   2   11 , Marco Arellano Albornoz  1   2   12 , Javier Pizarro-Berdichevsky  1   2   5
Affiliations

Sacral neuromodulation therapy for urinary and defecatory disorders: experience in a Latin American public hospital

Marcelo Mass-Lindenbaum et al. Rev Bras Ginecol Obstet. .

Abstract

Objective: To show the experience of a Latin American public hospital, with SNM in the management of either OAB, NOUR or FI, reporting feasibility, short to medium-term success rates, and complications.

Methods: A retrospective cohort was conducted using data collected prospectively from patients with urogynecological conditions and referred from colorectal surgery and urology services between 2015 and 2022.

Results: Advanced or basic trial phases were performed on 35 patients, 33 (94%) of which were successful and opted to move on Implantable Pulse Generator (GG) implantation. The average follow-up time after definitive implantation was 82 months (SD 59). Of the 33 patients undergoing, 27 (81%)reported an improvement of 50% or more in their symptoms at last follow-up. Moreover, 30 patients (90%) with a definitive implant reported subjective improvement, with an average PGI-I "much better" and 9 of them reporting to be "excellent" on PGI-I.

Conclusion: SNM is a feasible and effective treatment for pelvic floor dysfunction. Its implementation requires highly trained groups and innovative leadership. At a nation-wide level, greater diffusion of this therapy among professionals is needed to achieve timely referral of patients who require it.

Keywords: Electric stimulation therapy; Fecal incontinence; Incontinence; Non-obstructive urinary retention; Sacral neuromodulation; Urinary bladder; overactive.

PubMed Disclaimer

Conflict of interest statement

Conflicts to interest: none to declare

Figures

Figure 1
Figure 1. A: Spiculated Quadripolar electrode. B: Temporary Pulse Generator. C: Implantable Pulse Generator (Interstim II)
Figure 2
Figure 2. Peripheral nerve evaluation anatomic landmarks. Insulated needle on the left and electrode already delivered on the right side
Figure 3
Figure 3. Peripheral nerve evaluation electrodes connected to the external stimulator
Figure 4
Figure 4. Lateral view of optimal electrode placement, following the sacral root from cephalad to caudal direction
Figure 5
Figure 5. Antero-posterior view of optimal electrode placement, following the sacral root from medial to lateral, at the level of the sacroiliac joint where the S3 foramina is located
Figure 6
Figure 6. IImplantable Pulse Generator in subcutaneous pocket
Figure 7
Figure 7. Flow of patients
Figure 8
Figure 8. 5 years follow up of symptomatic improvement, defined as more than 50% compared to baseline
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Harries F. Introduction to sacral neuromodulation therapy for urinary bladder dysfunction using an InterStim system. Br J Nurs. 2020;29(9):S23–S26. doi: 10.12968/bjon.2020.29.9.S23. - DOI - PubMed
    1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. doi: 10.1002/nau.20798. - DOI - PubMed
    1. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–1580. doi: 10.1016/j.juro.2015.01.087. - DOI - PubMed
    1. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592–1604. doi: 10.1001/jama.2017.12137. - DOI - PubMed
    1. Bordeianou LG, Thorsen AJ, Keller DS, Hawkins AT, Messick C, Oliveira L, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence. Dis Colon Rectum. 2023;66(5):647–661. doi: 10.1097/DCR.0000000000002776. - DOI

LinkOut - more resources